Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW; COV-BARRIER Study Group.
. Mol Ecol Resour. 2014 May;14(3):606-15. doi: 10.1111/1755-0998.12205. Epub 2013 Dec 30. Mol Ecol Resour. 2014. PMID: 24266987
.
Markmiller S, et al. Cell Rep. 2021 Sep 7;36(10):109685. doi: 10.1016/j.celrep.2021.109685. Cell Rep. 2021. PMID: 34496257
. ![top](data:image/svg+xml,%3Csvg%20xmlns="http://www.w3.org/2000/svg"%20width="16"%20height="16"%3E%3Crect%20fill-opacity="0"/%3E%3C/svg%3E "top")
